2Chenguang W, Dingguo L. Legislative efforts for rare disease in China--analysis of the legal grounds and call for a regulatory framework[J].R. Dir. sanit. Sho Paulo, 2013.1(14): 11-33.
1TAO Y, SHAO Y F, ZHANG C, et al. The current situation of or?phan drug regulation in the United States[J]. 中国药学杂志,2001,36(9):634-636.
2LIU Y C, DONGJ P. Studies on management status of rare disea?ses and orphan drug in european union[J]. 中国药学杂志,2012,47(5):395-398.
3GONG S W. Study of management strategies of improoing access to orphan drugs in China[DJ. Wuhan: Huazhong University of Sci?ence and Technology, 2008.
4Department of Health, T AIW AN. Introduction and current situa?tion of TAIWAN Rare Diseases Regulation[EB/OL].[2012-01- 31J. http://www.doh.gov.tw.
5MA R, LI D G, ZHANG X, et al. Opportunities and challenges of rare disease prevention in China[J].中国循证儿科杂志,2011,6(2):81-82.
6FDA. Orphan Drug Act[EB/OLJ.[2012-03-14J. http://www. fda. gov/RegulatorylnformationiLegislationiFederalFoodDrugand?CosmeticActFDCActiSignificantAmendmentstotheFDCActlOr?phanDrugActidefault. htm.
7FDA. Priority NDA and BLA Approvals[EB/OLJ.[2012-05- 29J. http://www. fda. gov/Drugs/DevelopmentApprovalProcessl HowDrugsareDevelopedandApprovediDrugandBiologicApprov?alReports/PriorityNDAandBLAApprovalsl default. htm.
8FDA. Drug and Biologic Approval Reports[EB/OL].[2012-05- 29]. http://www. fda. gov/Drugs/DevelopmentApprovalProcessl HowDrugsareDevelopedandApprovediDrugandBiologicApprov?aIReportsl default. htm.
9FDA. About the Accelerated Approval Regulations[EB/OLJ .[2012-05-29J. http://www. fda. gov/Drugs/DevelopmentAp?provalProcess/HowDrugsareDevelopedandApprovediDrugandBio?logicApprovaIReportsl ucm121606. htm.
